Serum Proenkephalin A Levels and Mortality After Long-Term Follow-Up in Patients with Type 2 Diabetes Mellitus ZODIAC-32Reportar como inadecuado

Serum Proenkephalin A Levels and Mortality After Long-Term Follow-Up in Patients with Type 2 Diabetes Mellitus ZODIAC-32 - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.


Two previous studies concluded that proenkephalin A PENK-A had predictive capabilities for stroke severity, recurrent myocardial infarction, heart failure and mortality in patients with stroke and myocardial infarction.


This study aimed to investigate the value of PENK-A as a biomarker for predicting mortality in patients with type 2 diabetes mellitus.


Patients with type 2 diabetes mellitus were included from the prospective observational ZODIAC Zwolle Outpatient Diabetes project Integrating Available Care study. The present analysis incorporated two ZODIAC cohorts 1998 and 2001. Since blood was drawn for 1204 out of 1688 patients 71%, and information on relevant confounders was missing in 47 patients, the final sample comprised 1157 patients. Cox proportional hazard models were used for evaluating the relationship between PENK-A and cardiovascular mortality. Risk prediction capabilities were assessed with Harrell’s C statistics and the integrated discrimination improvement IDI.


After a follow-up period of 14 years, 525 45% out of 1157 patients had died, of which 224 43% were attributable to cardiovascular factors. Higher Log PENK-A levels were not independently associated with increased cardiovascular mortality. Patients with PENK-A values in the highest tertile had a 49% 95%CI 1%-121% higher risk of cardiovascular mortality compared to patients in the reference category lowest tertile. C-values were not different after removing PENK-A from the Cox models and there were no significant differences in IDI values.


The associations between PENK-A and mortality were strongly attenuated after accounting for all traditional risk factors. Furthermore, PENK-A did not seem to have additional value beyond conventional risk factors when predicting all-cause and cardiovascular mortality.

Autor: Kornelis J. J. van Hateren , Gijs W. D. Landman, Jarinke F. H. Arnold, Hanneke Joosten, Klaas H. Groenier, Gerjan J. Navis, Andre



Documentos relacionados